Abstract:Idiopathic pulmonary fibrosis (IPF) is characterized by permanent scarring of lung tissue and declining lung function, and is an incurable disease with increase in prevalence over the past decade. The current consensus is that aberrant wound healing following repeated injuries to the pulmonary epithelium is the most probable cause of IPF, with various immune inflammatory pathways having been reported to impact disease pathogenesis. While the role of immune cells, specifically T lymphocytes and regulatory T cells (Treg), in IPF pathogenesis has been reported and discussed recently, the pathogenic or beneficial roles of these cells in inducing or preventing lung fibrosis is still debated. This lack of understanding could be due in part to the difficulty in obtaining diseased human lung tissue for research purposes. For this reason, many animal models have been developed over the years to attempt to mimic the main clinical hallmarks of IPF: among these, inducing lung injury in rodents with the anti-cancer agent bleomycin has now become the most commonly studied animal model of IPF. Pulmonary fibrosis is the major side effect when bleomycin is administered for cancer treatment in human patients, and a similar effect can be observed after intra-tracheal administration of bleomycin to rodents. Despite many pathophysiological pathways of lung fibrosis having been investigated in bleomycin-injured animal models, one central facet still remains controversial, namely the involvement of specific T lymphocyte subsets, and in particular Treg, in disease pathogenesis. This review aims to summarize the major findings and conclusions regarding the involvement of immune cells and their receptors in the pathogenesis of IPF, and to elaborate on important parallels between animal models and the human disease. A more detailed understanding of the role of Treg and other immune cell subsets in lung injury and fibrosis derived from animal models is a critical basis for translating this knowledge to the development of new immune-based therapies for the treatment of human IPF.

Decreased Expression of B- and T-lymphocyte Attenuator (BTLA) is Associated with Progression of Disease in Idiopathic Pulmonary Fibrosis (IPF) (54.7)

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

Expression and Clinical Significance of B and T Lymphocyte Attenuator on CD4+ and CD8+ T Cells from Patients with Pulmonary Tuberculosis.

B-cell Activating Factor Regulates IL-1β- and IL-17A-mediated Pulmonary Fibrosis in Mice

B Cell Activating Factor is Central to Bleomycin- and IL-17-mediated Experimental Pulmonary Fibrosis.

Enhanced Bruton's tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

Mannan-Binding Lectin Reduces Epithelial-Mesenchymal Transition in Pulmonary Fibrosis Via Inactivating the Store-Operated Calcium Entry Machinery

BTLA Contributes to Acute-on-chronic Liver Failure Infection and Mortality Through CD4+ T-cell Exhaustion

Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis.

Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF.

Toll Interacting Protein Protects Lung Epithelial Cells from Bleomycin-Induced Apoptosis

Sustained high expression of BTLA on CD4+ T cell contributes to high rate of bacterial infection and mortality in patients with HBV-related acute-on-chronic liver failure via CD4+ T cell exhaustion

Therapeutic Effects of the Bcl-2 Inhibitor on Bleomycin-induced Pulmonary Fibrosis in Mice

Tertiary lymphoid structures and B-cell infiltration are IPF features with functional consequences

Increased Activated Regulatory T Cells Proportion Correlate with the Severity of Idiopathic Pulmonary Fibrosis

The potential role of interleukin (IL)-25/IL-33/thymic stromal lymphopoietin (TSLP) on the pathogenesis of idiopathic pulmonary fibrosis

Updates on the controversial roles of regulatory lymphoid cells in idiopathic pulmonary fibrosis

Allies or enemies? The effect of regulatory T cells and related T lymphocytes on the profibrotic environment in bleomycin-injured lung mouse models

CCL17 Drives Fibroblast Activation in the Progression of Pulmonary Fibrosis by Enhancing the TGF-β/Smad Signaling.

BTLA exhibits immune memory for αβ T cells in patients with active pulmonary tuberculosis.

BTLA exhibits immune memory for alpha beta T cells in patients with active pulmonary tuberculosis